Assembly Medicine(Shanghai), Co., Ltd.
Assembly Medicine LLC was founded by leading immunologists and biophysicists in October of 2017. We are devoted to converting innovative science and cutting edge technology to personalized precision medicine, thus fulfilling the growing demands for affordable cancer immunotherapy in China and Worldwide. Our internationally patented technology can achieve instant and precise assembly of multiple antibody fragments that target different antigens, to form multi-specific antibodies of any order of specificity. We are committed to sharing this technology with the world to maximize the potential and benefit of immunotherapy in our fight against cancer.
World’s leading MsAbs real-time self-assembly platform technology enables the unlimited preparation of various MsAbs or multiple valency recombinant protein drugs.
Our platform allows us to optimize MsAbs combination based on recent scientific findings and rapidly enlarging our unique MsAbs library.
Native Antigen technology is perfectly combined with antibody screening platforms, such as Phage display platform, Yeast display platform and hybridoma technology, to search for antibodies that precisely recognize distinct conformational or linear native epitopes.
With novel antibodies and combinations, our MsAbs self-assembly platform achieves targeted immunomodulation in the tumor microenvironment by leveraging the specificity of tumor recognition with the power of immune cells activation in a single antibody.
- 2-3F, Bldg.1, No.88 Da'erwen Rd., China(Shanghai) Pilot Free Trade Zone
- +021-5838-6095
- assembly@assemblymedicine.com